학술논문
Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
Document Type
Article
Author
Minson, Adrian; Hamad, Nada; Cheah, Chan Y.; Tam, Constantine S.; Blombery, Piers; Westerman, David A; Lade, Stephen; Ritchie, David; Koldej, Rachel M; Anderson, Mary Ann; Khot, Amit; Seymour, John F.; Robertson, Molly; Caldwell, Imogen R; Ryland, Georgina L; Xie, Jing; Morgan, Huw; Dickinson, Michael
Source
Blood; November 2022, Vol. 140 Issue: 1, Number 1 Supplement 1 p181-183, 3p
Subject
Language
ISSN
00064971; 15280020